𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization of the homo- and heterotypic immune responses after natural norovirus infection

✍ Scribed by Barry Rockx; Ralph S. Baric; Ingrid de Grijs; Erwin Duizer; Marion P.G. Koopmans


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
110 KB
Volume
77
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Noroviruses (NoV) are a genetically and antigenically diverse group of viruses that are common causes of outbreaks of gastroenteritis in humans of all ages. Limited information has been obtained on type specificity of the NoV immune response. In this study, we characterized the homologous and heterologous antibody responses in adults from 13 outbreaks, representing 4 different NoV genotypes. NoV specific IgG and IgA antibodies were determined as well as the increase of antibody avidity. In addition, antibody‐mediated blocking of NoV binding to its putative receptor was evaluated. Both homologous and heterologous serological responses were detected after NoV infection. The avidity of antibodies could not be used to distinguish between homologous and heterologous antibody responses. However, a homologous blocking response but not a heterologous response was detected after infection with NoV belonging to genogroup II.4 by a NoV ligand binding inhibition assay. Infection with NoV induces antibodies that can block virus ligand interactions. In contrast with all currently known antibody detection assays for NoV, this can be used as a type specific assay and may be an alternative for studying neutralizing antibodies. J. Med. Virol. 77:439–446, 2005. © 2005 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


The use of dried blood spots for assessi
✍ J.G. Melgaço; M.A. Pinto; A.M. Rocha; M. Freire; L.P. Gaspar; S.M.B. Lima; O.G. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

## Abstract During recent years, vaccination against hepatitis A has been implemented in several countries. It is expected that the increase in mass vaccination against hepatitis A will eventually result in a decreased prevalence of anti‐HAV antibodies in the general population. For this reason, a